spiramycin | CMAC

spiramycin

In vitro activity of macrolides against Streptococcus pneumoniae and Streptococcus pyogenes in the Russian Federation: “Status praesens”

Objective. To evaluate in vitro activity of various macrolide antibiotics against a current collection of clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes isolated from patients with community-acquired infections in different regions of the Russian Federation. Materials and Methods. A total of 350 clinical isolates from patients with community-acquired infections, including 200 S. pneumoniae and 150 S. pyogenes, were included in the study. To further evaluate the in vitro activity of 16-member macrolides against erythromycin-resistant isolates (MIC ≥ 0.

Potential for Use of Spiramycin in Clinical Practice

Spiramycin, natural 16-membered macrolide antibiotic, was discovered in 1954. This antimicrobial agent is at least non-inferior to and has some advantages over the currently available macrolides in spectrum of activity, pharmacological properties, …

Spiramycin: the classic and the present

Spiramycin is classic representative of the 16-membered macrolides, which was synthesized in 1954. Nevertheless he keeps his clinical significance due to the high activity against typical causative agents of respiratory tract, skin and soft tissues …